5 Best Biotech Stocks To Buy Now

2. Gilead Sciences, Inc. (NASDAQ:GILD)

Number of Hedge Fund Holders: 59

Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech firm with a research-based focus on the development, commercialization, and discovery of novel medications. The company has a strong portfolio in antiviral drugs and is also looking to expand its oncology segment. Phase 3 trials of breast cancer drug revealed increased survival by as much as 59%.

As of August 2022, Arrowstreet Capital owned $15.6 million shares in Gilead Sciences, Inc. (NASDAQ:GILD), valued at $968 million. The company made up 1.37% of the portfolio. At the end of Q2 2022, 59 hedge funds owned stakes in Gilead Sciences, Inc. (NASDAQ:GILD). The collective value of these stakes is over $3.99 billion.